Dysregulated Estrogen Receptor Signaling in the Hypothalamic-Pituitary-Ovarian Axis Leads to Ovarian Epithelial Tumorigenesis in Mice
Open Access
- 6 March 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 10 (3) , e1004230
Abstract
The etiology of ovarian epithelial cancer is poorly understood, mainly due to the lack of an appropriate experimental model for studying the onset and progression of this disease. We have created a mutant mouse model in which aberrant estrogen receptor alpha (ERα) signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis. In these mice, termed ERαd/d, the ERα gene was conditionally deleted in the anterior pituitary, but remained intact in the hypothalamus and the ovary. The loss of negative-feedback regulation by estrogen (E) at the level of the pituitary led to increased production of luteinizing hormone (LH) by this tissue. Hyperstimulation of the ovarian cells by LH resulted in elevated steroidogenesis, producing high circulating levels of steroid hormones, including E. The ERαd/d mice exhibited formation of palpable ovarian epithelial tumors starting at 5 months of age with 100% penetrance. By 15 months of age, 80% of ERαd/d mice die. Besides proliferating epithelial cells, these tumors also contained an expanded population of luteinized stromal cells, which acquire the ability to express P450 aromatase and synthesize E locally. In response to the elevated levels of E, the ERα signaling was accentuated in the ovarian epithelial cells of ERαd/d mice, triggering increased ERα-dependent gene expression, abnormal cell proliferation, and tumorigenesis. Consistent with these findings, treatment of ERαd/d mice with letrozole, an aromatase inhibitor, markedly reduced circulating E and ovarian tumor volume. We have, therefore, developed a unique animal model, which serves as a useful tool for exploring the involvement of E-dependent signaling pathways in ovarian epithelial tumorigenesis. Ovarian cancer is currently the most lethal gynecological cancer in the United States. Multiple epidemiological studies indicate that women who take hormone replacement therapy, estrogen or estrogen with progesterone, peri- or postmenopause will have an increased chance of developing ovarian cancer. Unfortunately, the five-year survival rate after diagnosis is very low indicating that better tools are needed to diagnose and treat ovarian cancer. The models that would allow investigation of this disease are severely limited. In this article we introduce a mouse model that develops epithelial ovarian tumors, and by employing inhibitors of estrogen synthesis, we show that ovarian tumorigenesis in this model is dependent on estrogen production within the ovarian tumor. These studies suggest that estrogen may play a role in promoting ovarian tumor growth.Keywords
This publication has 66 references indexed in Scilit:
- Minireview: Animal Models and Mechanisms of Ovarian Cancer DevelopmentEndocrinology, 2012
- High-grade serous ovarian cancer arises from fallopian tube in a mouse modelProceedings of the National Academy of Sciences, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Development of a Multimarker Assay for Early Detection of Ovarian CancerJournal of Clinical Oncology, 2010
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying TheoryAmerican Journal of Surgical Pathology, 2010
- Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literatureArchive of Oncology, 2010
- Cell Type–Specific Targeted Mutations of Kras and Pten Document Proliferation Arrest in Granulosa Cells versus Oncogenic Insult to Ovarian Surface Epithelial CellsCancer Research, 2009
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell CarcinomasClinical Cancer Research, 2009
- Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer riskEndocrine-Related Cancer, 2008